Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

References

• Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derivedfrom activated lymphoid cells. Blood. 1985;66(4):848–858.
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valetine M, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–1284. doi:10.1126/science.8122112.
   PubMed Web of Science ®Google Scholar
• Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol. 2015;22(1):29–49. doi:10.1097/PAP.0000000000000047.
   PubMed Web of Science ®Google Scholar
• Steven H, Swerdlow ECSA, Michele Ghielmini GASA. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569.
   PubMed Web of Science ®Google Scholar
• Swerdlow SHCEHN, Abramson JS. WHO classification of tumours of haematopoietic and lymphoid tissue(M). Lyon: IAＲC Press; 2008.
   Google Scholar
• Savage GHAK. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17–25. doi:10.1182/blood-2014-10-567461.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Govi S, Pileri SA, et al. Anaplastic large cell lymphoma, ALK- negative. Critical Reviews in Oncology/Hematology. 2013;85(2):206–215. doi: 10.1016/j.critrevonc.2012.06.004
   PubMed Web of Science ®Google Scholar
• Sibon D, Fournier M, Briere J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol. 2012;30(32):3939–3946. doi:10.1200/JCO.2012.42.2345.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Khan I, Mahon B, et al. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park). 2010;24(7):574–587.
   PubMed Web of Science ®Google Scholar
• Agnelli L, Mereu E, Pellegrino E, et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood. 2012;120(6):1274–1281. doi:10.1182/blood-2012-01-405555.
   PubMed Web of Science ®Google Scholar
• Ong DM, Cummins KD, Pham A, et al. PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement. BMJ Case Rep, 2015. doi:10.1136/ bcr-2015-211159.
   Google Scholar
• Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Annals of Oncology. 2014;25(11):2211–2217. doi: 10.1093/annonc/mdu443
   PubMed Web of Science ®Google Scholar
• Broussais-Guillaumot F, Coso D, Belmecheri N, et al. Peripheral T-cell lymphomas: analysis of histology,staging and response to treatment of 208 cases at a single institution. Leuk Lymphoma. 2013;54(11):2392–2398. doi:10.3109/10428194.2013.776680.
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. Journal of clinical oncology. 2013;31(16):1970–1976. doi: 10.1200/JCO.2012.44.7524
   PubMed Web of Science ®Google Scholar
• Morel A, Briere J, Lamant L, et al. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: a LYSA/SFGM-TC study. Eur J Cancer. 2017;83:146–153. doi:10.1016/j.ejca.2017.06.026.
   PubMed Web of Science ®Google Scholar
• Han X, Zhang W, Zhou D, et al. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: a single-centre experience. Journal of International Medical Research. 2017;45(1):290–302. doi: 10.1177/0300060516676725
   PubMed Web of Science ®Google Scholar
• Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2017;29(3):715–723. doi:10.1093/annonc/mdx787.
   Web of Science ®Google Scholar
• Wei J, Xu J, Cao Y, et al. Allogeneic stem-cell transplantation for peripheral T-cell lymphoma: a systemic review and meta-analysis. Acta Haematol. 2015;133(2):136–144. doi:10.1159/000358579.
   PubMed Web of Science ®Google Scholar
• Rohlfing S, Dietrich S, Witzens-Harig M, et al. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Annals of Hematology. 2018;97(7):1241–1250. doi: 10.1007/s00277-018-3288-7
   PubMed Web of Science ®Google Scholar
• Yang Y, Tai C, Chen C, et al. Highly diverse efficacy of salvage treatment regimens for relapsed or refractory peripheral T-cell lymphoma: a systematic review. Plos one. 2016;11(10):e161811), doi: 10.1371/journal.pone.0161811
   Web of Science ®Google Scholar
• Broccoli A, Argnani L, Zinzani PL. Peripheral T-cell lymphomas: focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev. 2017;60:120–129. doi: 10.1016/j.ctrv.2017.09.002
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–1189. doi: 10.1200/JCO.2010.29.9024
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–636. doi: 10.1200/JCO.2011.37.4223
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492–2499. doi: 10.1200/JCO.2014.59.2782
   PubMed Web of Science ®Google Scholar
• Shi Y, Dong M, Hong X, et al. Results from a multicenter,open-label,pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26:1766–1771. doi:10.1093/annonc/mdv237.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196. doi: 10.1200/JCO.2011.38.0402
   PubMed Web of Science ®Google Scholar
• Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Journal of Clinical Oncology. 2014;32(28):3137–3143. doi: 10.1200/JCO.2013.54.2456
   PubMed Web of Science ®Google Scholar
• Steven M, Horwitz RHAN, Tanya Siddiqi DAKA. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20). doi:10.1182/blood-2013-12-542142.
   Web of Science ®Google Scholar
• Zinzani PL, Sasse S, Radford J, et al. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: review of the literature. Critical Reviews in Oncology/Hematology. 2015;95(3):359–369. doi: 10.1016/j.critrevonc.2015.03.011
   PubMed Web of Science ®Google Scholar
• Mathilde Lamarque CBAC. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica. 2016;101(3):e103–e106. doi:10.3324/haematol.2015.135400.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–2717. doi:10.1182/blood-2017-05-780049.
   PubMed Web of Science ®Google Scholar
• Chihara D, Fanale MA. Management of anaplastic large cell lymphoma. Hematol Oncol Clin North Am. 2017;31(2):209–222. doi: 10.1016/j.hoc.2016.11.001
   PubMed Web of Science ®Google Scholar
• Arai H, Furuichi S, Nakamura Y, et al. ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. Rinsho Ketsueki. 2016;57(5):634–637. doi:10.11406/rinketsu.57.634.
   PubMedGoogle Scholar
• Al-Rohil RN, Torres-Cabala CA, Patel A, et al. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016;43(12):1161–1166. doi:10.1111/cup.12797.
   PubMed Web of Science ®Google Scholar
• Dai H, Wang Y, Lu X, et al. Chimeric antigen receptors Modified T-cells for cancer therapy. JNCI J Natl Cancer Inst. 2016;108(7):pii:djv439), doi: 10.1093/jnci/djv439
   Web of Science ®Google Scholar
• Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462–3471. doi:10.1172/JCI94306.
   PubMed Web of Science ®Google Scholar
• Perera LP, Zhang M, Nakagawa M, et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol. 2017;92(9):892–901. doi:10.1002/ajh.24794.
   PubMed Web of Science ®Google Scholar
• Molavi O, Xiong XB, Douglas D, et al. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. Biomaterials. 2013;34(34):8718–8725. doi:10.1016/j.biomaterials.2013.07.068.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Shin DY, Kim JS, et al. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol. 2016;27(4):712–718. doi:10.1093/annonc/mdv624.
   PubMed Web of Science ®Google Scholar
• Vu K, Ai W. Update on the treatment of anaplastic large cell lymphoma. Curr Hematol Malig Rep. 2018;13(2):135–141. doi: 10.1007/s11899-018-0436-z
   PubMed Web of Science ®Google Scholar
• Elisabetta Mereu EPIS. The heterogeneous landscape of ALK negative ALCL. Oncotarget. 2017;8(11):18525–18536. doi:10.18632/oncotarget.14503.
   PubMedGoogle Scholar
• Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473–1480. doi:10.1182/blood-2014-04-571091.
   PubMed Web of Science ®Google Scholar
• King RL, Dao LN, McPhail ED, et al. Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements. The American Journal of Surgical Pathology. 2016;40(1):36–43. doi: 10.1097/PAS.0000000000000500
   PubMed Web of Science ®Google Scholar
• Gritti G, Boschini C, Rossi A, et al. Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas. PLOS ONE. 2015;10(3):e121822), doi: 10.1371/journal.pone.0121822
   Web of Science ®Google Scholar
• Zhang XM, Li YX, Wang WH, et al. Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma. Eur J Haematol. 2013;90(3):195–201. doi:10.1111/ejh.12060.
   PubMed Web of Science ®Google Scholar
• Tsuyama N, Sakamoto K, Sakata S, et al. Anaplastic large cell lymphoma: pathology, genetics and clinical aspects. J Clin Exp Hematop. 2017;57(3):120–142. doi:10.3960/jslrt.17023.
   PubMed Web of Science ®Google Scholar
• Deng XW, Zhang XM, Wang WH, et al. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. Ann Hematol. 2016;95(8):1271–1280. doi:10.1007/s00277-016-2696-9.
   PubMed Web of Science ®Google Scholar
• Turner SD, Lamant L, Kenner L, et al. Anaplastic large cell lymphoma in paediatric and young adult patients. British Journal of Haematology. 2016;173(4):560–572. doi: 10.1111/bjh.13958
   PubMed Web of Science ®Google Scholar